Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Launched by CURTIN UNIVERSITY · Jun 26, 2025
Trial Information
Current as of July 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a medicine called tafenoquine behaves in the bodies of healthy children from Papua New Guinea. Tafenoquine is a drug being looked at as a possible treatment to fully clear a type of malaria called Plasmodium vivax, which is common in this region and can hide in the liver, causing the illness to come back later. Right now, a different medicine called primaquine is used to treat this, but tafenoquine might offer a simpler option. The study aims to understand how tafenoquine is processed in children's bodies to help determine the right dose and safety.
Children who might join the study need to be between about 5 and 12 years old, have normal levels of an important enzyme called G6PD (which helps protect red blood cells), and must not have malaria or have taken malaria medicine recently. Participants will need to visit the clinic several times for tests and monitoring, but they should be healthy with no other serious illnesses. This study is still preparing to start, and by taking part, children can help researchers find better ways to treat malaria in their community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • have a normal glucose-6-phosphate-dehydrogenase (G6PD) activity (\>70% enzyme activity) as confirmed by quantitative SD Biosensor
- • are Rapid Diagnostic Test negative for malaria
- • have not received treatment with any antimalarial in the previous 4-weeks
- • have no signs or symptoms of significant morbidity
- • have no history of hypersensitivity to primaquine
- • are able to attend all scheduled follow-up visits
- Exclusion Criteria:
- • have G6PD activity \<70%
- • test positive for malaria by rapid diagnostic test
- • have receive treatment with an antimalarial in the previous 4-weeks
- • have signs or symptoms of significant morbidities
- • have a history of primaquine related hypersensitivity
- • cannot, or are not willing, to attend all scheduled follow-up visits
About Curtin University
Curtin University is a leading Australian higher education institution known for its commitment to innovative research and academic excellence. With a strong emphasis on health sciences and clinical research, the university engages in a wide range of clinical trials aimed at advancing medical knowledge and improving patient outcomes. Leveraging its multidisciplinary expertise and state-of-the-art facilities, Curtin University collaborates with industry partners and healthcare organizations to conduct rigorous studies that address pressing health challenges. Through its dedication to ethical research practices and community engagement, Curtin University strives to contribute meaningfully to the global advancement of health and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madang, Madang Province, Papua New Guinea
Patients applied
Trial Officials
Brioni R Moore, PhD
Principal Investigator
Curtin University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported